Figure S8 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 8. The relative contribution of cfDNA from various tissues before and ~24 hours after surgery for pancreatic cancer. * p < 0.05, ** p < 0.01, *** p < 0.001</p

Supplementary Tables S1 and S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplementary Table 1. Demographic, clinical, and plasma cfDNA data for the patients included in the study deconvoluted by Sun et al. (3) and Moss et al. (43) by QP and NNLS. NA, not available. Supplementary Table 2. Demographic, clinical, and plasma cfDNA data for the patients included in the study deconvoluted by Loyfer et al. (44) NA, not available.</p

Figure S3 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 3. Fraction of plasma cfDNA that could be attributed to high molecular weight genomic DNA in samples analyzed by RealSeqS.</p

Figure S7 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 7. The amount of total cfDNA before and after surgery in patients with pancreatic cancer.</p

Figure S10 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 10. In silico mixing experiments (N = 10) of buffy coat bisulfite sequencing data with liver (A), lung (B), colon epithelial cell (C), and left atrium (D) bisulfite sequencing data deconvoluted using the Moss et al. (43) reference matrix and quadratic programming shows excellent agreement between predicted and actual fractional contribution.</p

Figure S9 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 9. Plasma AST and ALT levels before and ~24 hours after surgery for pancreatic cancer. AST and ALT levels substantially increased in all five patients.</p

Figure S5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 5. Methylation profiles using quadratic programming vs. non-negative least- squares regression using the reference matrix described in Moss et al. (43). Pearson’s correlation coefficient and p values are presented at the bottom of this figure, showing the derived contributions from each of the 25 tissue types that could be assessed.</p

Figure S1 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 1. Overview of the patient samples included in the present study.</p

Figure S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 2. The concentration of plasma cfDNA in previous described patients with cancer according to stage. (A) The concentration of cfDNA in patients of all cancer types (9). The concentration of cfDNA in patients with Stage III cancers was significantly higher than that of patients with Stage I cancers (p < 0.01). (B) The concentration of cfDNA in individual cancer types. Stage was classified according to AJCC 7th edition. The concentration of cfDNA in patients with Stage III breast cancer was significantly higher than that of patients with Stage I breast cancer (p < 0.05). For both panels, data were derived from the previously published CancerSEEK study (9).</p

Figure S6 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer

Supplemental Figure 6. Correlation between the cfDNA derived from colon epithelial cells, lung cells, and pancreatic cells, and the fraction of cfDNA derived from neoplastic colon epithelial cells, lung cells, or pancreatic cells.</p